Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient

被引：2
|
作者：
Ghosn, Marwan [1 ]
Dagher, Alain [1 ]
El-Karak, Fadi [1 ]
机构：
[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, 894 Blvd Alfred Naccache,Bldg Sehanoui,5th Floor, Beirut, Lebanon
来源：
JOURNAL OF BIOMEDICAL RESEARCH | 2015年 / 29卷 / 05期
关键词：
prostate-specific antigen; doubling time; prostate cancer; cabazitaxel; docetaxel;
D O I：
10.7555/JBR.28.20130148
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
引用
收藏
页码：420 / 422
页数：3
相关论文
共 50 条
  • [31] Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer
    Vickers, Andrew J.
    Savage, Caroline
    O'Brien, M. Frank
    Lilja, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) : 398 - 403
  • [32] Prostate-specific antigen doubling time as a predictor of prostate cancer disease progression and survival.
    Nelson, JB
    Allen, AR
    Hulting, SM
    Isaacson, JD
    Sleep, DS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 395S - 395S
  • [33] PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME AND DISEASE RELAPSE AFTER RADIOTHERAPY FOR PROSTATE-CANCER
    POLLACK, A
    ZAGARS, GK
    KAVADI, VS
    CANCER, 1994, 74 (02) : 670 - 678
  • [34] Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy
    Moreira, Daniel M.
    Gerber, Leah
    Thomas, Jean-Alfred
    Banez, Lionel L.
    McKeever, Madeline G.
    Freedland, Stephen J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (08) : 741 - 747
  • [35] The pretreatment prostate-specific antigen doubling time: clinical and prognostic values in patients with prostate cancer
    Zharinov, G. M.
    Bogomolov, O. A.
    ONKOUROLOGIYA, 2014, 10 (01): : 44 - 48
  • [36] Metastatic prostate cancer with a normal prostate-specific antigen level
    Ruiz-Martín I.
    Rodríguez-Sánchez C.A.
    Ocaña-Fernández A.
    Del Valle-Zapico J.
    De Prado-Otero D.S.
    Cruz-Hernández J.J.
    Clinical and Translational Oncology, 2005, 7 (9) : 412 - 413
  • [37] Value of mitoxantrone in hormone-resistant metastatic prostate cancer.
    Khalaf, A
    Pfister, C
    Hellot, MF
    Dunet, F
    Moussu, J
    Grise, P
    PROGRES EN UROLOGIE, 2002, 12 (01): : 37 - 42
  • [38] Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer
    McArdle, Peter A.
    Mir, Khurram
    Almushatat, A. S. K.
    Wallace, A. Michael
    Underwood, Mark A.
    McMillan, Donald C.
    UROLOGIA INTERNATIONALIS, 2006, 77 (02) : 127 - 129
  • [39] Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients
    Oudard, S.
    Banu, E.
    Scotte, F.
    Banu, A.
    Medioni, J.
    Beuzeboc, P.
    Joly, F.
    Ferrero, J. -M.
    Goldwasser, F.
    Andrieu, J. -M.
    ANNALS OF ONCOLOGY, 2007, 18 (11) : 1828 - 1833
  • [40] Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer
    Barbosa, Felipe G.
    Queiroz, Marcelo A.
    Ferraro, Daniela A.
    Nunes, Rafael F.
    Dreyer, Priscilla R.
    Zaniboni, Elaine C.
    Costa, Larissa B.
    Bastos, Diogo A.
    Marin, Jose Flavio G.
    Buchpiguel, Carlos A.
    RADIOGRAPHICS, 2020, 40 (05) : 1412 - 1430
12345